Virax Biolabs Group (VRAX) Balance Sheet: Assets & Liabilities

Virax Biolabs Group (VRAX) Balance Sheet

As of Mar 31, 2026 (end of fiscal 2026), Virax Biolabs Group reported total assets of $8.32M and total liabilities of $989.83K. Shareholders' equity was $7.58M, up 33.0% from $5.70M a year earlier. Total debt stood at $333.29K against $6.44M in cash and short-term investments, a net cash position of $6.11M. That puts debt-to-equity at 0.04, compared with 0.07 a year earlier.

Virax Biolabs Group Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Virax Biolabs Group Limited (VRAX) - Annual data in millions USD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022	FY 2021	FY 2020
Period ending	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Sep 2022	Mar 2022	Mar 2021	Mar 2020
Current Assets
Cash and Cash Equivalents	6.44	4.23	3.59	9.35	0.02	0.02	0.02	0.02
Short-Term Investments	0.08	0.00	0.00	0.05	0.00	0.01	0.00	0.00
Cash & Short-Term Investments	6.44	4.23	3.59	9.40	0.02	0.03	0.02	0.02
Accounts Receivable	0.03	0.03	0.22	0.00	0.00	-	0.00	0.00
Inventory	0.05	0.09	0.06	0.02	0.02	0.02	0.02	0.00
Other Current Assets	0.36	0.54	0.51	0.28	0.01	0.01	0.00	0.00
Total Current Assets	6.83	4.89	4.38	9.63	0.05	0.05	0.04	0.02
Non-Current Assets
Property, Plant & Equipment (Net)	1.50	1.53	1.10	0.00	0.00	-	0.00	0.00
Long-Term Investments	0.00	0.00	0.00	0.00	0.00	-	0.05	0.00
Intangible Assets	0.00	0.04	0.05	0.18	0.00	-	0.00	0.00
Other Non-Current Assets	0.00	-0.04	-0.05	-0.18	0.00	-	0.00	0.00
Total Non-Current Assets	1.50	1.53	1.10	0.18	0.00	-	0.05	0.00
Total Assets	8.32	6.43	5.48	9.81	0.05	0.05	0.09	0.02
Current Liabilities
Accounts Payable	0.05	0.06	0.05	0.72	0.85	1.24	0.22	0.21
Short-Term Debt	0.03	0.09	0.05	0.15	0.00	-	0.00	0.76
Accrued Liabilities	0.16	0.19	0.06	0.55	-	0.40	0.46	-
Deferred Revenue	0.00	0.00	0.00	0.04	0.00	-	0.00	-0.76
Other Current Liabilities	0.52	0.52	0.06	0.55	0.40	0.00	0.65	0.27
Total Current Liabilities	0.69	0.67	0.17	0.91	1.25	1.25	0.87	1.24
Non-Current Liabilities
Long-Term Debt	0.30	0.29	0.18	0.00	0.00	-	0.00	0.00
Other Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Total Non-Current Liabilities	0.30	0.29	0.18	0.00	0.00	-	0.00	0.00
Total Liabilities	0.99	0.96	0.35	0.91	1.25	1.25	0.87	1.24
Stockholders' Equity
Common Stock	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-29.61	-24.59	-18.53	-11.79	-6.34	-6.34	-4.63	-3.98
Accumulated Other Comprehensive Income	37.18	30.28	23.89	0.00	5.36	0.00	4.03	2.92
Minority Interest	-0.24	-0.23	-0.23	-0.22	-0.22	-0.22	-0.18	-0.16
Shares Outstanding	0.58	0.17	0.10	0.06	-	1.14	-	-
Total Stockholders' Equity	7.58	5.70	5.37	8.90	-0.97	-1.20	-0.60	-1.06
Total Liabilities & Equity	8.32	6.43	5.48	9.81	0.05	0.05	0.09	0.02

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About Virax Biolabs Group Balance Sheet

How much debt does Virax Biolabs Group have?

Virax Biolabs Group had total debt of $333.29K as of Mar 31, 2026, against $6.44M in cash and short-term investments. Its debt-to-equity ratio was 0.04. Total debt was $377.00K a year earlier.

What are Virax Biolabs Group's total assets?

Virax Biolabs Group reported total assets of $8.32M as of Mar 31, 2026, up 29.5% from $6.43M a year earlier. Total liabilities were $989.83K.

What is Virax Biolabs Group's shareholders' equity?

Virax Biolabs Group's shareholders' equity was $7.58M as of Mar 31, 2026, or about $13.08 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition